[Antibodies to the plasma membranes of thyrocytes in patients with diffuse toxic goiter during treatment with mercazole].
Antibodies to thyroid cell membranes (ATCM) were studied in sera from 49 patients with diffuse toxic goiter (DTG) using dot-immunobinding prior to treatment with mercazolyl and 1, 4, 12 and 24 mos. later. Among the DTG patients ATMC before treatment were detected in 75.5%; 4 mos. after the start of mercazolyl therapy ATCM were detected in 49% of the patients. Among patients in a long-term remission after mercazolyl therapy ATCM were detected in 37.5% pointing out to immunologic disturbance in these patients.
Saarma
V A
VA
Podar
T U
TU
D000293:Adolescent; D000328:Adult; D000368:Aged; D000906:Antibodies / Q000276:immunology*; D002462:Cell Membrane / Q000276:immunology; D005260:Female; D006042:Goiter / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D008297:Male; D008713:Methimazole / Q000627:therapeutic use*; D008875:Middle Aged; D013950:Thymus Gland / Q000276:immunology*
D000906:Antibodies; D008713:Methimazole
Antitela k plazamticheskim membranam tirotsitov u bol'nykh diffuznym toksicheskim zobom pri lechenii merkazolilom.